Lunit

Lunit Cash Conversion Cycle

The Cash Conversion Cycle (CCC) of Lunit (328130.KQ) as of Nov 5, 2026 is 199.61. In the previous year, Cash Conversion Cycle (CCC) was 227.96 — a change of -12.44% (lower).

Cash Conversion Cycle

199.61

YoY

-12.44%

Last updated:

Cash Conversion Cycle (CCC) of Lunit is 2024 199.61 . Cash Conversion Cycle (CCC) of Lunit was 2023 227.96 . It decreases by -12.44% lower compared to the previous year.

The Lunit Cash Conversion Cycle history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion Cycle
Date
Cash Conversion Cycle
Jan 1, 2019
55.51 KRW
Jan 1, 2020
790.45 KRW
Jan 1, 2021
38.91 KRW
Jan 1, 2022
190.85 KRW
Jan 1, 2023
227.96 KRW
Jan 1, 2024
199.61 KRW
The Lunit Cash Conversion Cycle history
YEARCash Conversion CycleYoY
199.61-12.44%
227.96+19.44%
190.85+390.45%
38.91-95.08%
790.45+1,323.90%
55.51—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Lunit Stock analysis

What does Lunit do? Lunit Inc is a South Korean company headquartered in Seoul, operating within the Health Care sector. The company has 293 employees and went public on July 21, 2022, with its ticker listed as 328130.KQ and ISIN KR7328130000. Lunit provides software solutions for medical diagnostic imaging services, focusing on the development and supply of AI-powered medical software. Its offerings include cancer diagnostic aid solutions, cancer early detection solutions, and cancer risk prediction solutions. The company's technology leverages artificial intelligence to enhance diagnostic capabilities in healthcare settings. Lunit's website is www.lunit.io, where further information about its services and solutions can be accessed. The company operates in the Health Care industry, specifically targeting medical imaging and AI-driven diagnostic tools. As of the latest available data, Lunit is engaged in the development and commercialization of AI-based medical software, aiming to improve the accuracy and efficiency of cancer-related diagnostics. The firm's IPO date marks its transition to a publicly traded company, reflecting its growth and market position in the healthcare technology space. Lunit's focus on AI applications in medical imaging positions it as a key player in the digital health sector, particularly within the Korean market and beyond. The company's solutions are designed to support healthcare professionals in making more informed diagnostic decisions, potentially reducing the time and resources required for cancer detection and treatment planning. Lunit is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Lunit stock

Cash Conversion Cycle (CCC) of Lunit is 199.61 in 2024.

Cash Conversion Cycle (CCC) of Lunit changed from 227.96 to 199.61, representing a -12.44% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Cycle (CCC) Lunit since 2006 – with annual values, charts, and detailed analysis.

The Cash Conversion Cycle measures how long it takes to convert inventory investments into cash from sales. A shorter CCC indicates more efficient working capital management.

CCC = DSO + DIO - DPO

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Cycle (CCC)'s Lunit with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Cycle (CCC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Cycle (CCC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Lunit

All Key Metrics — Lunit